Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus

Por Narwal, Rajesh, Roskos, Lorin K., Robbie, Gabriel J.
Publicado em 2013

Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients

Por Zheng, Bo, Yu, Xiang‐Qing, Greth, Warren, Robbie, Gabriel J.
Publicado no Br J Clin Pharmacol (2016)

Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children

Por Robbie, Gabriel J., Zhao, Liang, Mondick, John, Losonsky, Genevieve, Roskos, Lorin K.
Publicado em 2012

Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children

Por Robbie, Gabriel J., Zhao, Liang, Mondick, John, Losonsky, Genevieve, Roskos, Lorin K.
Publicado em 2012

Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation

Por Robbie, Gabriel J., Makari, Doris, Harris, Brian, Losonsky, Genevieve A., Jafri, Hasan S.
Publicado no Infect Dis Ther (2014)

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants

Por Forbes, Michael L, Kumar, Veena R, Yogev, Ram, Wu, Xionghua, Robbie, Gabriel J, Ambrose, Christopher S
Publicado no Hum Vaccin Immunother (2014)

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

Por Robbie, Gabriel J., Criste, Ryan, Dall'Acqua, William F., Jensen, Kathryn, Patel, Nita K., Losonsky, Genevieve A., Griffin, M. Pamela
Publicado em 2013

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults

Por Yu, Xiang-Qing, Robbie, Gabriel J., Wu, Yuling, Esser, Mark T., Jensen, Kathryn, Schwartz, Howard I., Bellamy, Terramika, Hernandez-Illas, Martha, Jafri, Hasan S.
Publicado no Antimicrob Agents Chemother (2016)

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects...

Por Pearlman David S, Miller S David, LaForce Craig, Oh Chad K, Parker Joseph M, Le Chenxiong, Robbie Gabriel J, White Wendy I, White Barbara, Molfino Nestor A
Publicado em 2011-02-01

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects...

Por Parker, Joseph M, Oh, Chad K, LaForce, Craig, Miller, S David, Pearlman, David S, Le, Chenxiong, Robbie, Gabriel J, White, Wendy I, White, Barbara, Molfino, Nestor A
Publicado em 2011